In CITCO, the latest bioinformatic tools are employed to support the development of novel and enhanced CAR-T and CAR-NK cell therapies. This includes the use of bulk RNA sequencing and single-cell RNA sequencing (scRNA-seq) for the characterization of T cells and NK cells, in-depth analysis and profiling of existing targets such as CD19 and BAFF-R, as well as the identification of potential new targets in lymphomas.
Furthermore, our bioinformatic research focuses on humanization of the antibodies utilized in constructing CARs, using newly developed algorithms for structural alignment of antibody structures.
Furthermore, our bioinformatic research focuses on humanization of the antibodies utilized in constructing CARs, using newly developed algorithms for structural alignment of antibody structures.